Overall clinical evaluation of cefpodoxime proxetil against infections in pediatric fields

Ryochi Fujii, Hidenori Meguro, Osamu Arimasu, Hiroaki Shiraishi, Toshiaki Abe, Hajime Yoshioka, Hiroshi Sakata, Kenichi Iseki, Yoji Takahashi, Koichi Murono, Yoshinori Wagatsuma, Akira Watanabe, Masahito Koshinami, Masaru Yokoyama, Shigeru Kimura, Mikio Minamitani, Kei Hachimori, Hiroshi Hayakawa, Yukishige Yanagawa, Haruo IchihashiHiroshi Hirosawa, Yasuko Ishikawa, Shintaro Takahashi, Hiroo Matsuda, Susumu Nakazawa, Hajime Satou, Kenji Niino, Akira Narita, Makoto Hori, Yoshikiyo Toyonaga, Morimasa Sugita, Keisuke Sunakawa, Hironobu Akita, Satoshi Iwata, Yoshitake Sato, Naoichi Iwai, Haruhi Nakamura, Mitsunobu Miyazu, Youichi Taneda, Kuniyoshi Kuno, Hiroshi Kimura, Hidetoshi Takeuchi, Hideki Ishikawa, Fumio Hayakawa, Naoki Yamamoto, Yoshikuni Nakao, Tadafumi Nishimura, Shigeyuki Aoki, Kazuo Tabuki, Yutaka Kobayashi, Tsunekazu Haruta, Shigekazu Kuroki, Takashi Motohiro, Yasutaka Sakata, Tohru Nishiyama, Kouji Ishimoto, Kaoru Tominaga, Fumio Yamashita, Kaoru Ajimine, Koichi Deguchi

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Dry syrup and tablet of newly developed Cefpodoxime proxetil (CS-807, CPDX-PR) was investigated in the departments of pediatrics of 17 institutes and their related hospitals. 1. Pharmacokinetics of CPDX-PR in pediatrics were investigated. Peak blood levels of CPDX at dose levels of 3 mg/kg and 6 mg/kg were 2.24±0.21 and 4.68±0.54 μg/ml, respectively, in fasting and 1.65±0.07 and 3.71+0.41 μg/ml, respectively, after meal. Urinary recovery rates in 6 hours were 31.2±2.2% of dose in average. 2. Clinical efficacies of CPDX-PR on various infectious diseases were studied in 748 cases. Clinical efficacy rate in 499 cases with causative bacteria isolated was 94.6%: efficacy rates for individual infections were 96.8% (120/124) for tonsillitis, 96.0% (96/100) for urinary tract infection, 93.5% (58/62) for pneumonia, 92.4% (61/66) for impetigo, 100% (32/32) for scarier fever and 93.2% for pharyngitis or laryngitis. Bacteriological eradication rate for Gram-positive organisms was 91.0% (244/268); and for Gram-negative organisms, 89.7% (210/234). The clinical efficacy rate for cases which were non-responsive to previous antibiotic therapy was 88.1% (74/84). 3. Side effects and clinical laboratory findings were investigated in 779 cases. Two each of vomiting, loose stool and rash, 10 of diarrhea and 1 of diarrhea associated with candidiasis were reported, but no serious side effects were noted. There was no serious laboratory test abnormality except slight elevations of eosinophile, platelet, transaminase or prolongation of prothrombin time, totalling 34 occurrences.

Original languageEnglish
Pages (from-to)1439-1455
Number of pages17
JournalThe Japanese Journal of Antibiotics
Volume42
Issue number7
DOIs
Publication statusPublished - 1989
Externally publishedYes

Fingerprint

cefpodoxime proxetil
Pediatrics
Diarrhea
Infection
Impetigo
Laryngitis
Tonsillitis
Pharyngitis
Candidiasis
Prothrombin Time
Transaminases
Exanthema
Eosinophils
Urinary Tract Infections
Tablets
Vomiting
Communicable Diseases
Meals
Fasting
Pneumonia

ASJC Scopus subject areas

  • Medicine(all)
  • Microbiology (medical)
  • Pharmacology (medical)
  • Infectious Diseases

Cite this

Fujii, R., Meguro, H., Arimasu, O., Shiraishi, H., Abe, T., Yoshioka, H., ... Deguchi, K. (1989). Overall clinical evaluation of cefpodoxime proxetil against infections in pediatric fields. The Japanese Journal of Antibiotics, 42(7), 1439-1455. https://doi.org/10.11553/antibiotics1968b.42.1439

Overall clinical evaluation of cefpodoxime proxetil against infections in pediatric fields. / Fujii, Ryochi; Meguro, Hidenori; Arimasu, Osamu; Shiraishi, Hiroaki; Abe, Toshiaki; Yoshioka, Hajime; Sakata, Hiroshi; Iseki, Kenichi; Takahashi, Yoji; Murono, Koichi; Wagatsuma, Yoshinori; Watanabe, Akira; Koshinami, Masahito; Yokoyama, Masaru; Kimura, Shigeru; Minamitani, Mikio; Hachimori, Kei; Hayakawa, Hiroshi; Yanagawa, Yukishige; Ichihashi, Haruo; Hirosawa, Hiroshi; Ishikawa, Yasuko; Takahashi, Shintaro; Matsuda, Hiroo; Nakazawa, Susumu; Satou, Hajime; Niino, Kenji; Narita, Akira; Hori, Makoto; Toyonaga, Yoshikiyo; Sugita, Morimasa; Sunakawa, Keisuke; Akita, Hironobu; Iwata, Satoshi; Sato, Yoshitake; Iwai, Naoichi; Nakamura, Haruhi; Miyazu, Mitsunobu; Taneda, Youichi; Kuno, Kuniyoshi; Kimura, Hiroshi; Takeuchi, Hidetoshi; Ishikawa, Hideki; Hayakawa, Fumio; Yamamoto, Naoki; Nakao, Yoshikuni; Nishimura, Tadafumi; Aoki, Shigeyuki; Tabuki, Kazuo; Kobayashi, Yutaka; Haruta, Tsunekazu; Kuroki, Shigekazu; Motohiro, Takashi; Sakata, Yasutaka; Nishiyama, Tohru; Ishimoto, Kouji; Tominaga, Kaoru; Yamashita, Fumio; Ajimine, Kaoru; Deguchi, Koichi.

In: The Japanese Journal of Antibiotics, Vol. 42, No. 7, 1989, p. 1439-1455.

Research output: Contribution to journalArticle

Fujii, R, Meguro, H, Arimasu, O, Shiraishi, H, Abe, T, Yoshioka, H, Sakata, H, Iseki, K, Takahashi, Y, Murono, K, Wagatsuma, Y, Watanabe, A, Koshinami, M, Yokoyama, M, Kimura, S, Minamitani, M, Hachimori, K, Hayakawa, H, Yanagawa, Y, Ichihashi, H, Hirosawa, H, Ishikawa, Y, Takahashi, S, Matsuda, H, Nakazawa, S, Satou, H, Niino, K, Narita, A, Hori, M, Toyonaga, Y, Sugita, M, Sunakawa, K, Akita, H, Iwata, S, Sato, Y, Iwai, N, Nakamura, H, Miyazu, M, Taneda, Y, Kuno, K, Kimura, H, Takeuchi, H, Ishikawa, H, Hayakawa, F, Yamamoto, N, Nakao, Y, Nishimura, T, Aoki, S, Tabuki, K, Kobayashi, Y, Haruta, T, Kuroki, S, Motohiro, T, Sakata, Y, Nishiyama, T, Ishimoto, K, Tominaga, K, Yamashita, F, Ajimine, K & Deguchi, K 1989, 'Overall clinical evaluation of cefpodoxime proxetil against infections in pediatric fields', The Japanese Journal of Antibiotics, vol. 42, no. 7, pp. 1439-1455. https://doi.org/10.11553/antibiotics1968b.42.1439
Fujii, Ryochi ; Meguro, Hidenori ; Arimasu, Osamu ; Shiraishi, Hiroaki ; Abe, Toshiaki ; Yoshioka, Hajime ; Sakata, Hiroshi ; Iseki, Kenichi ; Takahashi, Yoji ; Murono, Koichi ; Wagatsuma, Yoshinori ; Watanabe, Akira ; Koshinami, Masahito ; Yokoyama, Masaru ; Kimura, Shigeru ; Minamitani, Mikio ; Hachimori, Kei ; Hayakawa, Hiroshi ; Yanagawa, Yukishige ; Ichihashi, Haruo ; Hirosawa, Hiroshi ; Ishikawa, Yasuko ; Takahashi, Shintaro ; Matsuda, Hiroo ; Nakazawa, Susumu ; Satou, Hajime ; Niino, Kenji ; Narita, Akira ; Hori, Makoto ; Toyonaga, Yoshikiyo ; Sugita, Morimasa ; Sunakawa, Keisuke ; Akita, Hironobu ; Iwata, Satoshi ; Sato, Yoshitake ; Iwai, Naoichi ; Nakamura, Haruhi ; Miyazu, Mitsunobu ; Taneda, Youichi ; Kuno, Kuniyoshi ; Kimura, Hiroshi ; Takeuchi, Hidetoshi ; Ishikawa, Hideki ; Hayakawa, Fumio ; Yamamoto, Naoki ; Nakao, Yoshikuni ; Nishimura, Tadafumi ; Aoki, Shigeyuki ; Tabuki, Kazuo ; Kobayashi, Yutaka ; Haruta, Tsunekazu ; Kuroki, Shigekazu ; Motohiro, Takashi ; Sakata, Yasutaka ; Nishiyama, Tohru ; Ishimoto, Kouji ; Tominaga, Kaoru ; Yamashita, Fumio ; Ajimine, Kaoru ; Deguchi, Koichi. / Overall clinical evaluation of cefpodoxime proxetil against infections in pediatric fields. In: The Japanese Journal of Antibiotics. 1989 ; Vol. 42, No. 7. pp. 1439-1455.
@article{44f974e82ecc4bae866ac519f89cc45f,
title = "Overall clinical evaluation of cefpodoxime proxetil against infections in pediatric fields",
abstract = "Dry syrup and tablet of newly developed Cefpodoxime proxetil (CS-807, CPDX-PR) was investigated in the departments of pediatrics of 17 institutes and their related hospitals. 1. Pharmacokinetics of CPDX-PR in pediatrics were investigated. Peak blood levels of CPDX at dose levels of 3 mg/kg and 6 mg/kg were 2.24±0.21 and 4.68±0.54 μg/ml, respectively, in fasting and 1.65±0.07 and 3.71+0.41 μg/ml, respectively, after meal. Urinary recovery rates in 6 hours were 31.2±2.2{\%} of dose in average. 2. Clinical efficacies of CPDX-PR on various infectious diseases were studied in 748 cases. Clinical efficacy rate in 499 cases with causative bacteria isolated was 94.6{\%}: efficacy rates for individual infections were 96.8{\%} (120/124) for tonsillitis, 96.0{\%} (96/100) for urinary tract infection, 93.5{\%} (58/62) for pneumonia, 92.4{\%} (61/66) for impetigo, 100{\%} (32/32) for scarier fever and 93.2{\%} for pharyngitis or laryngitis. Bacteriological eradication rate for Gram-positive organisms was 91.0{\%} (244/268); and for Gram-negative organisms, 89.7{\%} (210/234). The clinical efficacy rate for cases which were non-responsive to previous antibiotic therapy was 88.1{\%} (74/84). 3. Side effects and clinical laboratory findings were investigated in 779 cases. Two each of vomiting, loose stool and rash, 10 of diarrhea and 1 of diarrhea associated with candidiasis were reported, but no serious side effects were noted. There was no serious laboratory test abnormality except slight elevations of eosinophile, platelet, transaminase or prolongation of prothrombin time, totalling 34 occurrences.",
author = "Ryochi Fujii and Hidenori Meguro and Osamu Arimasu and Hiroaki Shiraishi and Toshiaki Abe and Hajime Yoshioka and Hiroshi Sakata and Kenichi Iseki and Yoji Takahashi and Koichi Murono and Yoshinori Wagatsuma and Akira Watanabe and Masahito Koshinami and Masaru Yokoyama and Shigeru Kimura and Mikio Minamitani and Kei Hachimori and Hiroshi Hayakawa and Yukishige Yanagawa and Haruo Ichihashi and Hiroshi Hirosawa and Yasuko Ishikawa and Shintaro Takahashi and Hiroo Matsuda and Susumu Nakazawa and Hajime Satou and Kenji Niino and Akira Narita and Makoto Hori and Yoshikiyo Toyonaga and Morimasa Sugita and Keisuke Sunakawa and Hironobu Akita and Satoshi Iwata and Yoshitake Sato and Naoichi Iwai and Haruhi Nakamura and Mitsunobu Miyazu and Youichi Taneda and Kuniyoshi Kuno and Hiroshi Kimura and Hidetoshi Takeuchi and Hideki Ishikawa and Fumio Hayakawa and Naoki Yamamoto and Yoshikuni Nakao and Tadafumi Nishimura and Shigeyuki Aoki and Kazuo Tabuki and Yutaka Kobayashi and Tsunekazu Haruta and Shigekazu Kuroki and Takashi Motohiro and Yasutaka Sakata and Tohru Nishiyama and Kouji Ishimoto and Kaoru Tominaga and Fumio Yamashita and Kaoru Ajimine and Koichi Deguchi",
year = "1989",
doi = "10.11553/antibiotics1968b.42.1439",
language = "English",
volume = "42",
pages = "1439--1455",
journal = "The Journal of antibiotics. Ser. B",
issn = "0368-2781",
publisher = "Japan Antibiotics Research Association",
number = "7",

}

TY - JOUR

T1 - Overall clinical evaluation of cefpodoxime proxetil against infections in pediatric fields

AU - Fujii, Ryochi

AU - Meguro, Hidenori

AU - Arimasu, Osamu

AU - Shiraishi, Hiroaki

AU - Abe, Toshiaki

AU - Yoshioka, Hajime

AU - Sakata, Hiroshi

AU - Iseki, Kenichi

AU - Takahashi, Yoji

AU - Murono, Koichi

AU - Wagatsuma, Yoshinori

AU - Watanabe, Akira

AU - Koshinami, Masahito

AU - Yokoyama, Masaru

AU - Kimura, Shigeru

AU - Minamitani, Mikio

AU - Hachimori, Kei

AU - Hayakawa, Hiroshi

AU - Yanagawa, Yukishige

AU - Ichihashi, Haruo

AU - Hirosawa, Hiroshi

AU - Ishikawa, Yasuko

AU - Takahashi, Shintaro

AU - Matsuda, Hiroo

AU - Nakazawa, Susumu

AU - Satou, Hajime

AU - Niino, Kenji

AU - Narita, Akira

AU - Hori, Makoto

AU - Toyonaga, Yoshikiyo

AU - Sugita, Morimasa

AU - Sunakawa, Keisuke

AU - Akita, Hironobu

AU - Iwata, Satoshi

AU - Sato, Yoshitake

AU - Iwai, Naoichi

AU - Nakamura, Haruhi

AU - Miyazu, Mitsunobu

AU - Taneda, Youichi

AU - Kuno, Kuniyoshi

AU - Kimura, Hiroshi

AU - Takeuchi, Hidetoshi

AU - Ishikawa, Hideki

AU - Hayakawa, Fumio

AU - Yamamoto, Naoki

AU - Nakao, Yoshikuni

AU - Nishimura, Tadafumi

AU - Aoki, Shigeyuki

AU - Tabuki, Kazuo

AU - Kobayashi, Yutaka

AU - Haruta, Tsunekazu

AU - Kuroki, Shigekazu

AU - Motohiro, Takashi

AU - Sakata, Yasutaka

AU - Nishiyama, Tohru

AU - Ishimoto, Kouji

AU - Tominaga, Kaoru

AU - Yamashita, Fumio

AU - Ajimine, Kaoru

AU - Deguchi, Koichi

PY - 1989

Y1 - 1989

N2 - Dry syrup and tablet of newly developed Cefpodoxime proxetil (CS-807, CPDX-PR) was investigated in the departments of pediatrics of 17 institutes and their related hospitals. 1. Pharmacokinetics of CPDX-PR in pediatrics were investigated. Peak blood levels of CPDX at dose levels of 3 mg/kg and 6 mg/kg were 2.24±0.21 and 4.68±0.54 μg/ml, respectively, in fasting and 1.65±0.07 and 3.71+0.41 μg/ml, respectively, after meal. Urinary recovery rates in 6 hours were 31.2±2.2% of dose in average. 2. Clinical efficacies of CPDX-PR on various infectious diseases were studied in 748 cases. Clinical efficacy rate in 499 cases with causative bacteria isolated was 94.6%: efficacy rates for individual infections were 96.8% (120/124) for tonsillitis, 96.0% (96/100) for urinary tract infection, 93.5% (58/62) for pneumonia, 92.4% (61/66) for impetigo, 100% (32/32) for scarier fever and 93.2% for pharyngitis or laryngitis. Bacteriological eradication rate for Gram-positive organisms was 91.0% (244/268); and for Gram-negative organisms, 89.7% (210/234). The clinical efficacy rate for cases which were non-responsive to previous antibiotic therapy was 88.1% (74/84). 3. Side effects and clinical laboratory findings were investigated in 779 cases. Two each of vomiting, loose stool and rash, 10 of diarrhea and 1 of diarrhea associated with candidiasis were reported, but no serious side effects were noted. There was no serious laboratory test abnormality except slight elevations of eosinophile, platelet, transaminase or prolongation of prothrombin time, totalling 34 occurrences.

AB - Dry syrup and tablet of newly developed Cefpodoxime proxetil (CS-807, CPDX-PR) was investigated in the departments of pediatrics of 17 institutes and their related hospitals. 1. Pharmacokinetics of CPDX-PR in pediatrics were investigated. Peak blood levels of CPDX at dose levels of 3 mg/kg and 6 mg/kg were 2.24±0.21 and 4.68±0.54 μg/ml, respectively, in fasting and 1.65±0.07 and 3.71+0.41 μg/ml, respectively, after meal. Urinary recovery rates in 6 hours were 31.2±2.2% of dose in average. 2. Clinical efficacies of CPDX-PR on various infectious diseases were studied in 748 cases. Clinical efficacy rate in 499 cases with causative bacteria isolated was 94.6%: efficacy rates for individual infections were 96.8% (120/124) for tonsillitis, 96.0% (96/100) for urinary tract infection, 93.5% (58/62) for pneumonia, 92.4% (61/66) for impetigo, 100% (32/32) for scarier fever and 93.2% for pharyngitis or laryngitis. Bacteriological eradication rate for Gram-positive organisms was 91.0% (244/268); and for Gram-negative organisms, 89.7% (210/234). The clinical efficacy rate for cases which were non-responsive to previous antibiotic therapy was 88.1% (74/84). 3. Side effects and clinical laboratory findings were investigated in 779 cases. Two each of vomiting, loose stool and rash, 10 of diarrhea and 1 of diarrhea associated with candidiasis were reported, but no serious side effects were noted. There was no serious laboratory test abnormality except slight elevations of eosinophile, platelet, transaminase or prolongation of prothrombin time, totalling 34 occurrences.

UR - http://www.scopus.com/inward/record.url?scp=0024355401&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024355401&partnerID=8YFLogxK

U2 - 10.11553/antibiotics1968b.42.1439

DO - 10.11553/antibiotics1968b.42.1439

M3 - Article

C2 - 2681863

AN - SCOPUS:0024355401

VL - 42

SP - 1439

EP - 1455

JO - The Journal of antibiotics. Ser. B

JF - The Journal of antibiotics. Ser. B

SN - 0368-2781

IS - 7

ER -